Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 899-906

  Toi, Masakazu ^a   Ikeda, Tadashi ^b   Akiyama, Futoshi ^c   Kurosumi, Masafumi ^d   Tsuda, Hitoshi ^e   Sakamoto, Goi ^f   Abe, Osahiko ^g  

^a KYOTO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CANCER INSTITUTE   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^f Academy of Breast Pathology   (Japan)

^g ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Breast cancer; Dihydropyrimidine dehydrogenase; Predictive factor; Tegafur uracil; Thymidine phosphorylase; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; ESTROGEN RECEPTOR; TAMOXIFEN; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ARTICLE; BREAST TUMOR; CANCER STAGING; ENZYMOLOGY; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PREMENOPAUSE; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 35848963865     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.899     Document Type: Article

References (30)

1. Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K and Kodaira S: Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 36: 237-244, 2006.
2. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al: A randomized trial of adjuvant chemotherapy with uraciltegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
3. Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 386: 575-581, 2002.
4. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-2064, 2006.
5. Kasumi F, Yoshimoto M, Uchino J, Abe R, Nomura Y, Sugimachi K, et al: Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64: 146-153, 2003.
6. Yoshida M, Abe O, Uchino J, Kikuchi K, Abe R, Enomoto K, et al: Meta-analysis of the second collaborative study of adjuvant chemoendocrine therapy for breast cancer (ACETBC) in patients with stage II, estrogen-receptor-positive breast cancer. Breast Cancer 4: 93-101, 1997.
7. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, et al: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184, 2005. (Pubitemid 46218709)
8. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al: A phase II study of S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11: 194-202, 2004.
9. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
10. Toi M, Atiqur Rahman M, Bando H and Chow LW: Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6: 158-166, 2005.
11. Hayes DF: Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer 36: 302-306, 2000.
12. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002. (Pubitemid 34273259)
13. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, et al: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82: 560-567, 2000.
14. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000.
15. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77, 1998.
16. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, et al: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997.
17. Adlard JW, Richman SD, Seymour MT and Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3: 75-82, 2002. (Pubitemid 34162977)
18. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, et al: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
19. Xie W, Duan R, Chen I, Samudio I and Safe S: Transcriptional activation of thymidylate synthase by 17beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 141: 2439-2449, 2000.
20. Tominaga T, Toi M, Ohashi Y and Abe O: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 3: 55-64, 2002.
21. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, et al: Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6: 4409-4415, 2000.
22. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685-690, 1998. (Pubitemid 28099478)
23. Takechi T, Okabe H, Ikeda K, Fujioka A, Nakagawa F, Ohshimo H, et al: Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Rep 14: 33-39, 2005.
24. Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, et al: Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 38: 2375-2381, 2002.
25. Takechi T, Uchida J, Fujioka A and Fukushima M: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumour cells. Int J Oncol 11: 1041-1044, 1997.
26. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, et al: Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23: 4287-4297, 2005.
27. Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001. (Pubitemid 32366985)
28. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708, 1996.
29. EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
30. Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, et al: Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 90: 2338-2343, 2004.